Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION FPMAJ Drug Pricing Affairs Chief Lashes Out at Proposed Out-of-Cycle Re-Pricing
June 13, 2016
-
BUSINESS Takeda Looks to Join Top 10 List in Global Oncology Space in 2025
June 10, 2016
-
REGULATORY Upcoming ICH Meeting Expected to Approve New Members Including Generic Drug Organization
June 9, 2016
-
BUSINESS FY2015 Earnings Roundup - 3: Japan Market Stagnates despite No Drug Price Revision, Off-Patent Brands Weigh
June 8, 2016
-
BUSINESS FY2015 Earnings Roundup - 2: New Drugs Gain Traction Overseas to Underpin Japan Makers’ Financial Results
June 7, 2016
-
REGULATORY Use of MID-NET in PMS Could Promote Comparisons of One’s Own Products with Other Treatments: FPMAJ Official
June 7, 2016
-
BUSINESS FY2015 Earnings Roundup - 1: Operating Profits of Japan Makers Climb on Global Brands, Royalties
June 6, 2016
-
BUSINESS 27 Japan Drug Makers Derive Record 45.8% of Sales from Overseas Market: Jiho Tally
June 3, 2016
-
ORGANIZATION Japan Is at Crossroads, Must Carry On Its Pro-Innovation Policies: PhRMA Chairman
June 3, 2016
-
REGULATORY Tax Hike Delay Kills Feared Price Cuts in 2017, but Concerns Linger over Expensive Drug Debate
June 2, 2016
-
REGULATORY MHLW Initiates Discussions on Palliative Care for CV Diseases
June 1, 2016
-
REGULATORY Lawmakers Eye Genomic Medicine Bill to Fuel Diagnostics Development
May 31, 2016
-
REGULATORY AZ’s Ticagrelor, Boehringer’s Triple Combo Fail to Clear MHLW Advisory Panel
May 30, 2016
-
ORGANIZATION Sumitomo Dainippon Pres. Tada Picked as New Chief of FPMAJ
May 27, 2016
-
REGULATORY MHLW to Request Budgets to Promote Venture Companies in Response to Growth Strategy
May 26, 2016
-
REGULATORY MHLW to Begin Discussions this Fiscal Year on Regulation of Plasma Exports
May 25, 2016
-
BUSINESS Japan’s Top 3 Drug Makers Join Forces on Biomarker Research
May 24, 2016
-
BUSINESS Generic Makers Enjoy Revenue Rises as Govt Tailwinds Continue: Jiho Tally
May 23, 2016
-
REGULATORY Clinical Research Bill to Make It Easier for Companies to Provide Unapproved Drugs for Clinical Programs: LDP Lawmaker
May 20, 2016
-
REGULATORY Pricy Meds Again a Hot Topic at Chuikyo, MHLW Set to Launch Concrete Discussions
May 19, 2016
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…